<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR5">
 <label>5.</label>
 <mixed-citation publication-type="other">Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet [Internet]. 2017 Nov [cited 2019 Mar 8];390(10107):2063â€“72. Available from: 
  <ext-link ext-link-type="uri" xlink:href="https://linkinghub.elsevier.com/retrieve/pii/S0140673617322997" xmlns:xlink="http://www.w3.org/1999/xlink">https://linkinghub.elsevier.com/retrieve/pii/S0140673617322997</ext-link>.
 </mixed-citation>
</ref>
